尿閉治療の世界市場レポート 2025年

尿閉治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.3％で47億5,000万米ドルに成長します。予測期間中の成長予測は、在宅ケア需要の増加、前立腺がん症例数の増加、低侵襲手術の需要拡大、研究イニシアチブの増加、高齢者人口の増加などに起因しています。予測期間に予想される主な動向としては、新しく革新的な治療オプションの開発、尿失禁デバイスの進歩、技術革新、戦略的パートナーシップや提携、侵襲的なOTCデバイスの台頭、ウェアラブル技術の成長などが挙げられます。

前立腺がんの罹患率の増加は、予測期間中の尿閉治療市場の拡大を促進すると予想されます。前立腺がんは、前立腺における制御不能な細胞増殖を特徴とする悪性疾患です。前立腺がん患者の増加は主に人口動態の変化によるもので、高齢男性が増加しています。人口が高齢化するにつれて、前立腺がんを含む加齢関連疾患の発症リスクが増加します。尿閉治療は前立腺がん患者にとって不可欠です。なぜなら、腫瘍や肥大した前立腺が尿道を塞ぎ、排尿を困難にし、尿の流れを正常に戻す治療が必要になるからです。例えば、2024年6月、米国疾病予防管理センター（CDC）は、2022年に米国内の男性3万3,363人が前立腺がんで死亡し、2021年には23万6,659人が新たに前立腺がんと診断されたと報告しました。その結果、前立腺がんの症例数の増加が尿閉治療の需要を牽引することになります。

尿閉治療市場の主要企業は、膀胱と腸のコントロールを改善するために、次世代仙骨神経刺激療法などの先進技術に注力しています。仙骨神経刺激療法は、軽度の電気刺激で仙骨神経を刺激し、尿閉や過活動膀胱の症状を緩和します。例えば、2022年2月、アイルランドを拠点とする医療機器企業Medtronic Plcは、米国食品医薬品局（FDA）からInterStim Xシステムの承認を受け、個別化された仙骨神経刺激療法が大きく前進しました。InterStim Xシステムは、長持ちする充電不要のバッテリー、MRI対応、オーダーメイド治療のためのスマートプログラマーを特徴としています。また、2段階の植え込みプロセスにより、永続的な植え込みの前に試用期間を設けることができます。これらの技術革新により、膀胱と腸のコントロールの利便性と安全性が向上しました。InterStimシステムには、充電不要のInterStim Xと充電可能なInterStim Microの2つの長期オプションがあり、どちらも過活動膀胱や慢性便失禁などの症状向けに設計されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の尿閉治療のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の尿閉治療市場：成長率分析
• 世界の尿閉治療市場の実績：規模と成長、2019～2024年
• 世界の尿閉治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の尿閉治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の尿閉治療市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• 5α還元酵素阻害剤・α遮断薬
• 抗コリン薬または抗けいれん薬
• 抗うつ薬
• 骨格筋弛緩薬
• 局所エストロゲン
• その他
• 世界の尿閉治療市場：失禁の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 腹圧性尿失禁
• 切迫性尿失禁
• 溢流性尿失禁
• 混合性尿失禁
• その他
• 世界の尿閉治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 膀胱内
• 静脈内
• 経皮
• 世界の尿閉治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 小売薬局
• 病院薬局
• オンライン薬局
• 世界の尿閉治療市場：5α還元酵素阻害剤・α遮断薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• フィナステリド
• デュタステリド
• タムスロシン
• アルフゾシン
• テラゾシン
• ドキサゾシン
• 世界の尿閉治療市場：抗コリン薬または抗けいれん薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オキシブチニン
• トルテロジン
• ソリフェナシン
• ダリフェナシン
• トロスピウム
• フェソテロジン
• 世界の尿閉治療市場：抗うつ薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• イミプラミン
• アミトリプチリン
• デュロキセチン
• 世界の尿閉治療市場：骨格筋弛緩薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• バクロフェン
• チザニジン
• ジアゼパム
• シクロベンザプリン
• 世界の尿閉治療市場：局所エストロゲンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エストラジオールクリーム
• 結合型エストロゲン
• エストリオール膣クリーム
• 世界の尿閉治療市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ボツリヌス毒素（ボトックス）
• ミラベグロン
• デスモプレシン

第7章 地域別・国別分析

• 世界の尿閉治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の尿閉治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 尿閉治療市場：競合情勢
• 尿閉治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline Plc.
• Medtronic Plc
• Eli Lilly and Company
• Boston Scientific Corp.
• Sumitomo Pharma Inc.
• Ipsen Pharma
• Coloplast A/S
• Dr. Reddy's Laboratories
• Cipla Limited
• Amneal Pharmaceuticals Inc.
• Ferring Pharmaceuticals
• Otsuka Pharmaceutical Co. Ltd.
• NYMOX CORPORATION
• Antev Ltd.
• Amber Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 尿閉治療市場2029：新たな機会を提供する国
• 尿閉治療市場2029：新たな機会を提供するセグメント
• 尿閉治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Urinary retention therapeutics encompass a range of medical treatments designed to address the inability to fully empty the bladder. These therapies aim to relieve bladder pressure, restore normal urinary flow, and prevent complications such as infections or kidney damage. The primary objective is to improve bladder function and enhance the patient's comfort and overall quality of life.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main urinary retention therapeutics include 5-alpha-reductase inhibitors and alpha-blocker drugs, anticholinergic or antispasmodic agents, antidepressants, skeletal muscle relaxants, topical estrogens, and others. 5-alpha-reductase inhibitors and alpha-blocker drugs are commonly used to treat benign prostatic hyperplasia (BPH). The former works by reducing prostate size through blocking the hormone dihydrotestosterone (DHT), while the latter helps relax muscle fibers in the prostate and bladder neck to improve urine flow. These treatments are used for conditions such as stress incontinence, urge incontinence, overflow incontinence, mixed incontinence, and others. They are administered through various routes, including oral, intravesical, intravenous, and transdermal, and are distributed through channels such as retail pharmacies, hospital pharmacies, and online pharmacies.

The urinary retention therapeutics market research report is one of a series of new reports from The Business Research Company that provides urinary retention therapeutics market statistics, including urinary retention therapeutics industry global market size, regional shares, competitors with a urinary retention therapeutics market share, detailed urinary retention therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the urinary retention therapeutics industry. This urinary retention therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urinary retention therapeutics market size has grown strongly in recent years. It will grow from$3.33 billion in 2024 to $3.58 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historical period can be attributed to the rising incidence of urological disorders, increased healthcare spending, a growing global geriatric population, a higher prevalence of urinary incontinence (UI), and an escalating risk of related urological conditions among individuals.

The urinary retention therapeutics market size is expected to see strong growth in the next few years. It will grow to$4.75 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The projected growth during the forecast period can be attributed to the increasing demand for home-based care, a rising number of prostate cancer cases, growing demand for minimally invasive procedures, an increase in research initiatives, and a larger geriatric population. Key trends expected in the forecast period include the development of new and innovative treatment options, the advancement of urinary incontinence devices, technological innovations, strategic partnerships and collaborations, the rise of invasive OTC devices, and the growth of wearable technologies.

The growing incidence of prostate cancer is expected to drive the expansion of the urinary retention therapeutics market during the forecast period. Prostate cancer is a malignant condition characterized by uncontrolled cell growth in the prostate gland. The rise in prostate cancer cases is primarily due to demographic changes, with more men living longer lives. As the population ages, the risk of developing age-related diseases, including prostate cancer, naturally increases. Urinary retention therapeutics are vital for prostate cancer patients because the tumor or an enlarged prostate can block the urethra, making urination difficult and requiring treatments to restore normal urine flow. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that 33,363 men in the United States died from prostate cancer in 2022, while 236,659 new cases were diagnosed in 2021. Consequently, the growing number of prostate cancer cases will drive the demand for urinary retention therapeutics.

Key companies in the urinary retention therapeutics market are focusing on advanced technologies, such as next-generation sacral nerve stimulation therapy, to improve bladder and bowel control. Sacral nerve stimulation therapy uses mild electrical impulses to stimulate the sacral nerves, helping relieve symptoms of urinary retention or overactive bladder. For instance, in February 2022, Medtronic Plc, an Ireland-based medical device company, received approval from the U.S. Food and Drug Administration (FDA) for its InterStim X system, marking a significant advancement in personalized sacral nerve stimulation therapy. The InterStim X system features a long-lasting, recharge-free battery, MRI compatibility, and a smart programmer for tailored therapy. Its two-stage implantation process allows for a trial period before permanent placement. These innovations enhance the convenience and safety of managing bladder and bowel control. The InterStim systems offer two long-term options: the recharge-free InterStim X and the rechargeable InterStim Micro, both designed for conditions such as overactive bladder and chronic fecal incontinence.

In September 2023, Caldera Medical, a U.S.-based medical device company specializing in women's health, acquired Atlantic Therapeutics for an undisclosed amount. This acquisition allows Caldera Medical to expand its women's health portfolio by integrating the FDA-cleared Innova product family, which provides non-invasive treatments for stress urinary incontinence (SUI). Atlantic Therapeutics, an Ireland-based medical technology company, focuses on bladder control treatments, aligning with the urinary retention therapeutics market.

Major players in the urinary retention therapeutics market are Pfizer Inc., Merck KGaA, Abbvie Inc., Bayer AG, Sanofi SA, GlaxoSmithKline Plc., Medtronic Plc, Eli Lilly and Company, Boston Scientific Corp., Sumitomo Pharma Inc., Ipsen Pharma, Coloplast A/S, Dr. Reddy's Laboratories, Cipla Limited, Amneal Pharmaceuticals Inc., Ferring Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., NYMOX CORPORATION, Antev Ltd., Amber Therapeutics, Implantica Patent Ltd.

North America was the largest region in the urinary retention therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in urinary retention therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urinary retention therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary retention therapeutics market consists of revenues earned by entities by providing services such as drug development and formulation services, clinical trial management, regulatory consulting and medical device integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary retention therapeutics market also includes sales of catheters, prostate shrinking agents, urethral stents and sacral neuromodulation devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urinary Retention Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urinary retention therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urinary retention therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary retention therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs; Anticholinergic Or Antispasmodic Agents; Antidepressants; Skeletal Muscle Relaxants; Topical Estrogens; Other Drugs
• 2) By Incontinence Type: Stress Incontinence; Urge Incontinence; Over-Flow Incontinence; Mixed Incontinence; Other Incontinence Types
• 3) By Administration Route: Oral; Intravesical; Intravenous; Transdermal
• 4) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
• Subsegments:
• 1) By 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs: Finasteride; Dutasteride; Tamsulosin; Alfuzosin; Terazosin; Doxazosin
• 2) By Anticholinergic or Antispasmodic Agents: Oxybutynin; Tolterodine; Solifenacin; Darifenacin; Trospium; Fesoterodine
• 3) By Antidepressants: Imipramine; Amitriptyline; Duloxetine
• 4) By Skeletal Muscle Relaxants: Baclofen; Tizanidine; Diazepam; Cyclobenzaprine
• 5) By Topical Estrogens: Estradiol Cream; Conjugated Estrogens; Estriol Vaginal Cream
• 6) By Other Drugs: Botulinum Toxin (Botox); Mirabegron; Desmopressin
• Companies Mentioned: Pfizer Inc.; Merck KGaA; Abbvie Inc.; Bayer AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urinary Retention Therapeutics Market Characteristics

3. Urinary Retention Therapeutics Market Trends And Strategies

4. Urinary Retention Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Urinary Retention Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urinary Retention Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urinary Retention Therapeutics Market Growth Rate Analysis
• 5.4. Global Urinary Retention Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urinary Retention Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urinary Retention Therapeutics Total Addressable Market (TAM)

6. Urinary Retention Therapeutics Market Segmentation

• 6.1. Global Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs
• Anticholinergic Or Antispasmodic Agents
• Antidepressants
• Skeletal Muscle Relaxants
• Topical Estrogens
• Other Drugs
• 6.2. Global Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stress Incontinence
• Urge Incontinence
• Over-Flow Incontinence
• Mixed Incontinence
• Other Incontinence Types
• 6.3. Global Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravesical
• Intravenous
• Transdermal
• 6.4. Global Urinary Retention Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy
• 6.5. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Finasteride
• Dutasteride
• Tamsulosin
• Alfuzosin
• Terazosin
• Doxazosin
• 6.6. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Anticholinergic or Antispasmodic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oxybutynin
• Tolterodine
• Solifenacin
• Darifenacin
• Trospium
• Fesoterodine
• 6.7. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imipramine
• Amitriptyline
• Duloxetine
• 6.8. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Skeletal Muscle Relaxants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Baclofen
• Tizanidine
• Diazepam
• Cyclobenzaprine
• 6.9. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Topical Estrogens, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estradiol Cream
• Conjugated Estrogens
• Estriol Vaginal Cream
• 6.10. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Botulinum Toxin (Botox)
• Mirabegron
• Desmopressin

7. Urinary Retention Therapeutics Market Regional And Country Analysis

• 7.1. Global Urinary Retention Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urinary Retention Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urinary Retention Therapeutics Market

• 8.1. Asia-Pacific Urinary Retention Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urinary Retention Therapeutics Market

• 9.1. China Urinary Retention Therapeutics Market Overview
• 9.2. China Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urinary Retention Therapeutics Market

• 10.1. India Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urinary Retention Therapeutics Market

• 11.1. Japan Urinary Retention Therapeutics Market Overview
• 11.2. Japan Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urinary Retention Therapeutics Market

• 12.1. Australia Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urinary Retention Therapeutics Market

• 13.1. Indonesia Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urinary Retention Therapeutics Market

• 14.1. South Korea Urinary Retention Therapeutics Market Overview
• 14.2. South Korea Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urinary Retention Therapeutics Market

• 15.1. Western Europe Urinary Retention Therapeutics Market Overview
• 15.2. Western Europe Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urinary Retention Therapeutics Market

• 16.1. UK Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urinary Retention Therapeutics Market

• 17.1. Germany Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urinary Retention Therapeutics Market

• 18.1. France Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urinary Retention Therapeutics Market

• 19.1. Italy Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urinary Retention Therapeutics Market

• 20.1. Spain Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urinary Retention Therapeutics Market

• 21.1. Eastern Europe Urinary Retention Therapeutics Market Overview
• 21.2. Eastern Europe Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urinary Retention Therapeutics Market

• 22.1. Russia Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urinary Retention Therapeutics Market

• 23.1. North America Urinary Retention Therapeutics Market Overview
• 23.2. North America Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urinary Retention Therapeutics Market

• 24.1. USA Urinary Retention Therapeutics Market Overview
• 24.2. USA Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urinary Retention Therapeutics Market

• 25.1. Canada Urinary Retention Therapeutics Market Overview
• 25.2. Canada Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urinary Retention Therapeutics Market

• 26.1. South America Urinary Retention Therapeutics Market Overview
• 26.2. South America Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urinary Retention Therapeutics Market

• 27.1. Brazil Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urinary Retention Therapeutics Market

• 28.1. Middle East Urinary Retention Therapeutics Market Overview
• 28.2. Middle East Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urinary Retention Therapeutics Market

• 29.1. Africa Urinary Retention Therapeutics Market Overview
• 29.2. Africa Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urinary Retention Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Urinary Retention Therapeutics Market Competitive Landscape
• 30.2. Urinary Retention Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Urinary Retention Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Plc.
• 31.2. Medtronic Plc
• 31.3. Eli Lilly and Company
• 31.4. Boston Scientific Corp.
• 31.5. Sumitomo Pharma Inc.
• 31.6. Ipsen Pharma
• 31.7. Coloplast A/S
• 31.8. Dr. Reddy's Laboratories
• 31.9. Cipla Limited
• 31.10. Amneal Pharmaceuticals Inc.
• 31.11. Ferring Pharmaceuticals
• 31.12. Otsuka Pharmaceutical Co. Ltd.
• 31.13. NYMOX CORPORATION
• 31.14. Antev Ltd.
• 31.15. Amber Therapeutics

32. Global Urinary Retention Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urinary Retention Therapeutics Market

34. Recent Developments In The Urinary Retention Therapeutics Market

35. Urinary Retention Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Urinary Retention Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urinary Retention Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urinary Retention Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35005_Urinary_Retention_Therapeutics_GMR_2025